Article in HTML

Author(s): Nadeem Shaikh1*1, Sagar Patidar22, Manish Mukati23, Rakesh Punasiya24

Email(s): 1nadeemshaikh3090@gmail.com

Address:

    1. Ali-Allana College of Pharmacy Akkalkuwa, Dist. Nandurbar Maharashtra India 425415 2. Yogeshwar College of pharmacy Piplaj, Dist. Barwani Madhya Pradesh India 451551

Published In:   Volume - 5,      Issue - 1,     Year - 2026


Cite this article:
Nadeem Shaikh, Sagar Patidar, Rakesh Punasiya, Rakesh Punasiya. Formulation and Evaluation of Gastroretentive Floating Microspheres of Labetalol Hydrochloride. IJRPAS, January 2026; 5(12): 33-39.

  View PDF

Please allow Pop-Up for this website to view PDF file.




Formulation and Evaluation of Gastroretentive Floating Microspheres of Labetalol Hydrochloride

Nadeem Shaikh1*; Sagar Patidar2; Manish Mukati2; Rakesh Punasiya2

 

1.Ali-Allana College of Pharmacy Akkalkuwa, Dist. Nandurbar Maharashtra India 425415          

2. Yogeshwar College of pharmacy Piplaj, Dist. Barwani Madhya Pradesh India 451551

 

*Correspondence: nadeemshaikh3090@gmail.com;

DOI: https://doi.org/10.71431/IJRPAS.2026.5104

Article Information

 

Abstract

Research Article

Received: 13/01/2026

Accepted: 26/01/2026

Published:31/01/2026

 

Keywords

Labetalol hydrochloride, Gastroretentive drug delivery, Floating microspheres, Sustained release, Ethyl cellulose, Eudragit RS100.

 

 

Labetalol hydrochloride is an antihypertensive drug exhibiting extensive first-pass metabolism and a relatively short biological half-life, necessitating frequent dosing which may reduce patient compliance. The present investigation aimed to formulate and evaluate gastroretentive floating microspheres of labetalol hydrochloride to prolong gastric residence time and provide sustained drug release. Floating microspheres were prepared by the emulsion solvent diffusion method using ethyl cellulose and Eudragit RS100 as release-controlling polymers and polyvinyl alcohol as a surfactant. Preformulation studies confirmed the physicochemical suitability of the drug. FT-IR studies revealed no chemical interaction between the drug and polymers. The prepared microspheres were evaluated for flow properties, particle size, percentage yield, entrapment efficiency, in vitro buoyancy, and in vitro drug release. The microspheres exhibited good flow properties, high buoyancy (76–94%), and sustained drug release up to 12 hours. Among all formulations, F8 showed optimum characteristics with highest entrapment efficiency (97.2%), buoyancy (94%), and controlled drug release up to 12 hours. The study concludes that gastroretentive floating microspheres of labetalol hydrochloride can be an effective approach to enhance oral bioavailability and improve patient compliance.

 

INTRODUCTION

Oral drug delivery is the most convenient and widely accepted route due to ease of administration and better patient compliance. However, drugs with short half-life, narrow absorption window, or extensive first-pass metabolism often show reduced bioavailability. Gastroretentive drug delivery systems (GRDDS) are designed to retain the dosage form in the stomach for a prolonged period, thereby enhancing drug absorption and therapeutic efficacy.

Floating microspheres are low-density multiarticulate systems that remain buoyant over gastric contents, enabling prolonged gastric retention and controlled drug release. Labetalol hydrochloride, a combined alpha- and beta-adrenergic blocker, is widely used in the management of hypertension but requires frequent dosing due to its short half-life. Hence, it was selected as a suitable candidate for the development of a gastroretentive floating microsphere system.

MATERIALS AND METHODS

Floating microspheres of labetalol hydrochloride were prepared by the emulsion solvent diffusion method using ethyl cellulose and Eudragit RS100 as polymers. Polyvinyl alcohol was used as a surfactant. The prepared microspheres were subjected to Preformulation and evaluation studies including flow properties, particle size analysis, percentage yield, entrapment efficiency, in vitro buoyancy, and in vitro drug release studies.

Table 1. List of materials used

Sr. No.

Name of the Material

Manufacturer /Supplier

Role in formulation

1.

Labetalol hydrochloride

Gift sample from Glan

Pharma Pvt. Ltd., Hyderabad.

Active ingredient

2.

Ethyl cellulose

Loba Chemie Pvt. Ltd.Mumbai

Polymer

3.

Eudragit RS100

Yarrow Chem Mumbai

Polymer

4.

Polyvinyl Alcohol

Loba Chemie Pvt. Ltd.Mumbai

Stabilizing agent

5.

Ethanol

Loba Chemie Pvt. Ltd.Mumbai

Solvent

6

Dichloromethane

Loba Chemie Pvt. Ltd.Mumbai

Solvent

7

Hydrochloric acid

Loba Chemie Pvt. Ltd.Mumbai

Solvent

 

Table 2. List of Equipment /Instruments used

Sr. No.

Equipment’s

Manufacturers/Suppliers

1.

Electronic Weighing Balance

MC Dalal.

2.

FT-IR

Nicolet, Germany.

3.

Uv-visible Spectrophotometer

Shimadzu 1800

4.

Magnetic Stirrer

Remi instruments, Mumbai.

5.

Scanning Electron Microscope

Hitachi, Japan.

6.

Optical Microscope

Sigma Scientific Instrumentation.

7.

pH meter

Electronics India

8.

Hot air oven

Lab Tech

9.

Dissolution Apparatus

EI Instruments

10.

Stability chamber

Remi Che-6 Plus

 

Table 3. Composition of Formulation

 

 

F. CODE

 

Labetalol Hydrochloride

(mg)

 

Ethyl Cellulose

(mg)

 

Eudragit RS100

(mg)

Polyvinyl Alcohol

(0.5%w/v)

(ml)

 

Ethanol:

Dichloromethane (1:1)

F1

100

100

--

100

10:10

F2

100

200

--

100

10:10

F3

100

300

--

100

10:10

F4

100

--

100

100

10:10

F5

100

--

200

100

10:10

F6

100

--

300

100

10:10

F7

100

100

100

100

10:10

F8

100

200

100

100

10:10

F9

100

100

200

100

10:10

 

RESULT AND DISCUSSION

Preformulation studies indicated that labetalol hydrochloride possessed suitable physicochemical characteristics for formulation. The λmax was found at 246 nm and the drug obeyed Beer-Lambert’s law in the concentration range of 20–100 µg/ml (R² = 0.999). FT-IR spectra confirmed the absence of any drug–polymer interaction.

λmax Determination by UV Spectroscopy:

The maximum absorption (λmax) of Labetalol HCl Was found at 246.00 nm and iso-absorptive point at 243.48 nm. Absorption for a series of standard Solutions were recorded at selected wavelength.

 

 

 


 

Fig: - 01 Absorption spectra of labetalol HCL

 

 CHEMICAL COMPATIBILITY:
 FT-IR Spectroscopic Studies:

FT-IR spectroscopy gives the possible information about the interaction between the drug and the polymer. The compatibility between drug and polymer was confirmed by using FT-IR spectroscopy. Infrared spectroscopic analysis for drug (Labetalol hydrochloride), drug polymer admixture and formulations were carried out.


 

       Fig: -02 FT-IR spectrum of Labetalol Hydrochloride

 

Preformulation studies of labetalol hydrochloride microspheres

All formulations were evaluated for flow properties and the results were shown in table

Table:04 Flow property measurements of Microspheres

F. code

Bulk density (g/ml) *

Tapped density (g/ml) *

Carr’s Index (%) *

Hausner’sratio

Angle of repose (θ)

F1

0.32± 0.009

0.35± 0.009

6.37 ± 1.72

1.01

36°52

F2

0.34± 0.012

0.36±0.007

6.51 ± 1.91

1.06

37°68

F3

0.47 ±0.03

0.52 ± 0.02

10.63 ± 0.03

1.11

25°41

F4

0.34 ± 0.016

0.36 ± 0.011

6.55 ± 1.90

1.05

35°18

F5

0.35 ± 0.009

0.38±0.009

6.69 ± 2.05

1.07

39°47

F6

0.35± 0.011

0.38± 0.006

6.73 ± 1.84

1.07

34°55

F7

0.32±0.05

0.39±0.06

6.78 ± 0.09

1.04

38°52

F8

0.49 ±0.01

0.54 ± 0.01

10.20 ± 0.02

1.10

33°50

F9

0.31±0.04

0.37±0.08

7.10±0.07

1.04

36°40

 

Inference: The formulations F3 and F8 showed good flow property.

 

All formulations exhibited acceptable flow properties. Particle size ranged from 55.4 µm to 219.33 µm and increased with polymer concentration. Percentage yield ranged between 48.33% and 86.25%, while entrapment efficiency varied from 80.5% to 97.2%. In vitro buoyancy studies demonstrated that microspheres remained buoyant for more than 12 hours. In vitro drug release studies revealed sustained release behavior, with formulation F8 showing controlled drug release up to 12 hours and was selected as the optimized formulation.

Table:05 In vitro drug release for all formulations

Time

(hrs.)

 

 

PERCENTAGE

DRUG

RELEASE

 

 

 

 

 

 

Time

(hrs.)

 

 

F1

F2

F3

F4

F5

F6

F7

F8

F9

 

 

0

0

0

0

0

0

0

0

0

0

 

2.55

2.25

1.8

2.16

0.7

1.51

0.36

1.62

1.98

0.5

 

15.54

9.38

9.38

6.5

10.71

3.88

1.44

10.54

9.02

1

 

29.48

16.68

16.68

20.16

16.86

10.76

23.49

13.27

10.38

1.5

 

38.38

32.08

21.18

28.8

25.24

16.55

34.28

22.6

20.93

2

 

47.59

36.84

34.83

45.63

35.6

27.9

37.27

24.01

24.76

3

 

59.21

45.79

42.05

49.28

53.35

40.35

51

35.35

46.09

4

 

61.59

52.77

56.45

70.33

61.05

47.81

60.92

37.44

59.38

5

 

91.54

66.75

64.8

75.87

71.61

70.29

72.1

47.83

68.7

6

 

94.38

73.77

69.37

86.78

75.08

83.83

80.98

50.06

80.62

7

 

96.9

84.64

81.44

96.86

81.19

-

94.44

57.43

86.16

8

 

-

87.52

85.55

-

85.65

-

-

62.81

90.86

9

 

-

97.8

87.89

-

90.42

-

-

73.73

93.8

10

 

-

-

93.21

-

-

-

-

87.83

96.94

11

 

-

-

99.04

-

-

-

-

100.2

98.25

12

 

0

0

0

0

0

0

0

0

0

 

Fig: -03 In vitro release of Optimized formulations

The comparative in vitro release profile for Labetalol Hydrochloride Microspheres (F3&F8) were shown in Figure No. 29. The results of formulations show (99.04% and 100.2%) controlled release up to 12th The entrapment efficiency was found to be higher in F3- 93.4%±0.21 and F8- 97.2% comparatively with other formulations. Therefore, F3 and F8 were selected as formulations

CONCLUSION

Gastroretentive floating microspheres of labetalol hydrochloride were successfully formulated using ethyl cellulose and Eudragit RS100. The optimized formulation (F8) demonstrated excellent buoyancy, high entrapment efficiency, and sustained drug release up to 12 hours. This delivery system has the potential to improve oral bioavailability, reduce dosing frequency, and enhance patient compliance in the management of hypertension.

REFERENCES       

1.    Ramu S, Suneetha D, Srinivas R & Ramakrishna G. Formulation and Evaluation of Gastroretentive Clarithromycin Floating Tablets, International Journal Of pharmaceutical, Chemical and Biological Sciences,2015; 5(4): 883-895.

2.    Pant Shailaja, Badola Ashutosh, kothiyal Preeti “A REVIEW ON GASTRORETENTIVE DRUG DELIVERY SYSTEM” International Journal of Research and Development in Pharmacy and Life Sciences, June – July, 2016;5(4):2178-2179.

3.    Shaikh Siraj, Molvi Khurshid. I, Sayyed Nazim “Various Perspectives of Gastro retentive Drug Delivery System: A Review” American Journal of Advanced Drug Delivery,2013;1(4):1-2.

4.    Shakya.R , Thapa P & Saha.NR. In Vitro and In Vivo Evaluation of Gastroretentive Floating Drug Delivery System of Ofloxacin, Asian Journal of Pharmaceutical Sciences,2013; 1(1): 91-98.

5.    Ali J, Arora S, Ahuja A, Babbar AK, Sharma RK, Khar RK, Baboota S. Formulation and Development of Hydrodynamically balanced system for metformin: in vitro and in vivo Evaluation. European journal of Pharmaceutics and biopharmaceutics.2007 Aug 31;67(1):196-201.

6.    Katakam V.K, Somagoni J.M, Reddy S, Eaga C.M, Rallabandi B.R.C and Yamsani MR. Floating Drug Delivery Systems: A Review. 2010;4(2):610-647.

7.    Vinod K.R, Vasa S, Anbuazaghan S, Banji D, Padmasri A and Sandhya S.

Approaches For gastrotentive drug delivery systems. IJABPT. 2010;1(1) 589-60.

8.    Dhole AR, Gaikwad PD, Bankar VH, Pawar SP. A Review on Floating Multiparticulate Drug Delivery System- A Novel Approach to Gastric Retentionists. 2011; 6(2): 205 -211.

9.    Garg R and Gupta G.D. Progress in controlled Gastroretentive delivery. Trop J PharRes. 2008; 7(3):1055-1066.

10.    Ganesh N.S, Suraj Mahadev Ambale, Ramesh B, Kiran B and Deshpande. An Overview On limitations of Gastroretentive drug delivery System. IJPSRR.2011; 8 (2):133-139.

11.    Kawatra M, Jain U, Ramana J. Recent Advances in Floating Microspheres as Gastro-Retentive drug delivery System: A Review. International Journal of Recent Advances in Pharmaceutical Research. July 2012; 2(3): 5-23.

12.    Dhadde Gurunath S., Mali Hanmant S., Raut Indrayani D., Nitalikar Manoj M., Bhutkar Mangesh A., A Review on Microspheres: Types, Method of Preparation, Characterization and Application,Asian Journal of Pharmacy and Technology, June 2021;11(2):1-2.

13.    Tarun Virmani, et. Al., Pharmaceutical Application of Microspheres: An Approach for The Treatment of Various Diseases, International Journal of Pharmaceutical Sciences and Research, 2017, 7 Page 3252-3260.

14.    B. Sree Giri Prasad, et. Al., Microspheres as Drug Delivery System – A Review, Journal Of Global Trends in Pharmaceutical Sciences, (2014), 5(3), Page 1961–1972.

15.    Saravana Kumar K, et. Al., A Review on Microsphere for Novel Drug delivery System, Journal of Pharmacy Research, 2012,5(1), Page 420-424.

16.    Pande AV, Vaidya PD, Arora M, Dhoka MV. In Vitro and In Vivo Evaluation of Ethyl Cellulose Based Floating Microspheres of Cefpodoxime Proxetil. International Journal of Pharmaceutical and Biomedical Research. 2010, 1(4):122-128.

17.    Mastiholimath.V. S, Dandagi PM, Gadad AP, Mathews R, Kulkarni A. R. In vitro And  in  vivo  evaluation  of Ranitidine  hydrochloride  ethyl cellulose  floating Microparticles. J. Microencapsulation. 2008, 25(5), 307-314.

18.    Ghodake JD, Vidhate JS, Shinde DA, Kadam AN. Formulation and Evaluation of Floating Microsphere Containing Anti-Diabetic (Metformin Hydrochloride) Drug. International Journal of PharmTech Research. 2010, 2(1): 378-384

19.    Kamila MM, Mondal N, Ghosh LK, Gupta BK. Multiunit floating drug delivery System of rosiglitazone maleate: development, characterization, statistical Optimization of drug release and in vivo evaluation. AAPS PharmSciTech. 2009, 10(3):887-99

20.    Gattani YS, Kawtikwar PS, Sakarkar DM. Formulation and evaluation of Gastro Retentive Multiarticulate Drug delivery system of Aceclofenac International Journal of Chemtech Research. 2009, 1(1): 1-10.

21.    Fentie M, Belete A, Mariam TG Formulation of Sustained Release Floating Microspheres of Furosemide from Ethyl cellulose and Hydroxypropyl Methylcellulose Polymer Blends. J Nano med Nanotechnology. 2015, 6: 262.

22.    Peru Mandla PK, Priya S. Formulation And In Vitro Evaluation of Floating Microspheres of Dextromethorphan Hydrobromide. International Journal of Pharmacy  and Pharmaceutical Sciences. 2014, 6 (4): 206-210.

23.    Panwar MS, Tanwar YS. Development and characterization of sustain release Gastro retentive floating microsphere of diltiazem hydrochloride for the treatment of hypertension. Asian J Pharm 2015; 9: 107-12.

24.    Pandey N, Sah AN, Mahara K. Formulation and Evaluation of Floating Microspheres of Nateglinide. International Journal of Pharma Sciences and Research. 2016, 7 (11): 453-464.

25.    Kaushik AY, Tiwari AK, Gaur A. Preparation of Floating Microspheres of Valsartan: In-Vitro Characterization. Int. J. Res. Ayurveda Pharm. 2015; 6(1):124-130.

26.    Saxena A, Gaur K, Singh V, Singh RK, Dashora A. Floating Microspheres as Drug Delivery System. AJPPS 2014, 1(2):27-36.

27.    Devi NA, Vijendar C, Anil Goud K, Anil Kumar D, Khaja M and Anil A. Preparation and Evaluation of Floating Microspheres of Cefdinir in Treatment of Otitis Media and Respiratory Tract Infections. J Pharmacovigilance 2016, 4:3

28.    Bhuvaneswari S, Manivannan S, Akshay M, Nify F. Formulation and Evaluation of Gastroretentive Microballoons of Acebrophylline for the Treatment of Bronchial Asthma. Asian J Pharm Clin Res, 2016, 9(5):105-111.

29.    Verma          NK,    Alam    G,    Mishra    JN,    Vishwakarma    DK.   Formulation and Characterization of floating microspheres of Ibuprofen. Int J Res Pharm Sci 2015, 5(1); 18 22.31.

30.    Sharma MK. Formulation and Characterization of Floating Microspheres of Acarbose by Solvent Evaporation Method. Mintage journal of Pharmaceutical & Medical Sciences. 2016, 5 (3): 3-7.

31.    Chouhan M, Chundawat AVS, Chauhan C. S. Development and Characterization of Floating Microspheres of Esomeprazole Magnesium Trihydrate by Solvent Evaporation Method. IJPSR, 2017; Vol. 8(2): 686-697

32.    Yadav S, Nyola NK, Jeyabalan G, Gupta M. Gastroretentive drug delivery System: a concise review. Int J Res Pharm Sci 2016, 6(2); 19 –24.

33.    Hafeez A, Maurya A, Singh J, Mittal A, Rana L. An overview on floating Microsphere: Gastro Retention Floating drug delivery system (FDDS). The Journal of Phytopharmacology 2013; 2(3): 1-12.

34.    Patel S, Aundhia C, Seth A, Shah N, Gohil D, Ramani V. Design, Development, Evaluation and Optimization of Micro balloons of Telmisartan. Saudi J. Med. Pharm. Sci., Vol-4, Iss-1A (Jan, 2018): 70-89

35.    Shivani BR, Sailaja AK. Preparation and Evaluation of Floating Microspheres of Omeprazole Microspheres by Solvent Evaporation Method. International Journal Of

Basic and Applied Chemical Sciences.2015, 5 (3):67-78.

36.    J Josephine LJ, Mehul RT, Wilson B, Shanaz B, Bincy R. Formulation and In Vitro Evaluation of Floating Microspheres of Anti-Retro Viral Drug as a Gastro Retentive Dosage Form. IJRPC. 2011, 1(3): 519-527.

37.    Vasava K, Rajesh KS, Jha LL. Formulation and Evaluation of Floating Microspheres of Cephalexin. International Journal of Pharmaceutical Sciences Review and Research. 2011, 11(2): 69-75.

38.    Sharma AK, Keservani RK., Dadar Wal SC, Choudhary YL, Ramteke S. Formulation and in vitro characterization of cefpodoxime proxetil gastroretentive Micro balloons DARU. 2011,19(1): 33-40.

 

 

 

 

 

 

 

 

 

 

 

 

 



Related Images: